EP MedSystems Sponsors Heart Rhythm Society
Symposium May 4, 2005

WEST BERLIN, N.J.--(BUSINESS WIRE)--May 2, 2005--EP MedSystems, Inc. (NASDAQ: EPMD - News), announced today that it will sponsor a symposium on May 4th, 2005 in conjunction with this week's Heart Rhythm Society's Heart Rhythm 2005 Conference. The Symposium is entitled "Novel Technologies in the International Electrophysiology Laboratory: State-of-the-Art 2005". This symposium will focus on several new technologies that are being developed for second-generation interventional electrophysiology laboratories.

The technologies presented at the symposium spotlight two areas of interest. First, intracardiac echocardiography, which continues to be an important component of interventional electrophysiologic procedures, has more recently been used in cardiac pacing procedures. Secondly, three dimensional physiologic mapping and navigation now permits complex ablation procedures, including atrial fibrillation interventions. While new stimulation modes and catheters based defibrillation have become necessary during these procedures to facilitate diagnosis and confirm treatment. These new technologies have provided the clinical practitioner with new capabilities in the laboratory during a wide array of procedures.

This symposium will highlight the major technologic developments, essentials of imaging using these novel technologies, interpretation of these images and clinical applications using a wide array of interventional EP procedures. The program features international leaders in the fields of intracardiac echocardiography imaging, mapping and interventional electrophysiologic therapies. Didactic lecturers are supplemented by a moderated panel discussion and questions-and-answer periods.

The symposium's director is Sanjeev Saksena, MD, Clinical Professor of Medicine, Robert Wood Johnson Medical School. The Symposium's faculty will also include: John Hummel, MD, FACC, Attending Electrophysiologist, Riverside Medical Center; Jonathan Kalman, MD, MRCP, Assistant Professor of Medicine, Royal Melbourne Hospital; Bradley Knight, MD, FACC, Assistant Professor of Medicine, University of Chicago; Luc Jordaens, MD FESC, Professor of Cardiology, University of Rotterdam; Andrea Natale, MD, FACC, Professor of Medicine, Cleveland Clinical School of Medicine; Hugh Calkins, Professor of Medicine and Pediatrics, John Hopkins University School of Medicine and Director of Electrophysiology Laboratory & Arrhythmia Service, D avid Haines, Director, Heart Rhythm Center, William Beaumont Hospital; Fred Kusumoto, Senior Associate Consultant, Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Benjamin Scherlag, George Lynn Cross Research Professor, Helen Webster Professor of Cardiac Arrhythmia, Professor of Medicine, Cardiac Arrhythmia Research Institute, University of Oklahoma Health Sciences Center.

About EP MedSystems:
EP MedSystems develops and markets cardiac electrophysiology ("EP") products used to diagnose and treat certain cardiac rhythm disorders. The Company's EP product line includes the EP-WorkMate® Electrophysiology Workstation with RPM(TM) Real-time Position Management(TM) navigation technology, the EP-4(TM) Computerized Cardiac Stimulator, fixed and deflectable diagnostic electrophysiology catheters and related disposable supplies, the ALERT® System and ALERT family of internal cardioversion catheters, and the ViewMate® intracardiac ultrasound catheter imaging. For more information, visit our Website at www.epmedsystems.com.

Forward Looking Statements:
This Release may contain certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Forward-looking statements include information concerning our possible or assumed future results of operations and statements preceded by, followed by or including the words "believes", "expects", "anticipates", "intends", "plans", "estimates", "see opportunities" or similar expressions. Such forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such forward-looking statements are only predictions and are subject to risks and uncertainties that could cause actual results or events to differ materially and adversely from the events discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, EP MedSystems' history of losses, uncertainty of market acceptance of our products and level of sales, uncertainty of future profitability and future liquidity needs, possible costs, fines or penalties that may be incurred in connection with government inquiries and investigations and risks regarding regulatory approvals and demand for new and existing products, as stated in the Company's Annual Report filed on Form 10-KSB and quarterly reports filed on Form 10-Q and 10-QSB.

EP MedSystems cautions investors and others to review the cautionary statements set forth in this press release and in EP MedSystems' reports filed with the Securities and Exchange Commission and cautions that other factors may prove to be important in affecting the EP MedSystems' business and results of operations. Readers are cautioned not to place undue reliance on this press release and other forward-looking statements, which speak only as of the date of this release. EP MedSystems undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.

For Further Information Contact:

EP MedSystems, Inc.
Matthew C. Hill
(856)753-8533

Investor Relations Firm:
MKR Group, LLC
Charles Messman, Todd Kehrli
(818)556-3700